Immunovia publishes prospectus regarding preferential

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 26, 2016 at 7:45 AM

Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia publishes prospectus regarding preferential rights issue Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”). Publication of prospectus Immunovia’s prospectus, prepared in connection with the Rights Issue, has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus has today been published and is also available on the company’s web page http://immunovia.com/investors/ and the Company’s head office. Time table for the Rights Issue 26 September 2016 Last day of trading in the shares including subscription rights. 27 September 2016 First day of trading in the shares without the right to participate in the Rights Issue. 28 September 2016 Record date for participation in the Rights Issue. Registered shareholders included in the share register held by Euroclear Sweden AB will receive subscription rights carrying the right to participate in the Rights Issue. 3 October ‑ 17 October 2016 Subscription period. 3 October ‑ 13 October 2016 Trading in subscription rights. 3 October - 26 October 2016 Trading in paid subscribed shares (sw. BTA). 20 October 2016 The outcome of the Rights Issue is announced. Beginning of November The Rights Issue is completed and registered. Advisors Vator Securities AB is financial advisor to Immunovia and Baker & McKenzie Advokatbyrå KB is legal advisor to Vator Securities AB and Immunovia in connection with the Rights Issue. For further information, contact: Mats Grahn, CEO Immunovia AB Phone: +46 (0)70-532 02 30 E-mail: mats.grahn@immunovia.com This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CET on 26 September 2016. About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com. IMPORTANT INFORMATION This press release is not an offer or solicitation to acquire shares in Immunovia. A prospectus relating to the Rights Issue referred to in this press release will be filed with the Swedish Financial Supervisory Authority. After approval and registration of the prospectus by the Swedish Financial Supervisory Authority, the prospectus will be published and made available on i.e. Immunovia’s website. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Immunovia does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations. ###

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Michael Lee-Chin: Wealth Strategies and Life Lessons

Embracing Opportunity and Adversity When you think of someone who’s made a real dent in the business world, Michael Lee-Chin’s journey might just stop you in your tracks. Here’s a guy who went from standing on the 'dunce' side of the class in Jamaica to transforming himself into one of the few Black billionaires on this planet. That transformation is no small feat,...

Revolutionizing Textiles: Touchscreen Garments Emerge

Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...

CTG Data Breach Sparks Class Action Investigation

CTG Faces Scrutiny Over Recent Data Breach Ah, the thrills and spills of the digital age—yet another company stumbling headfirst into a data breach mess. This time, it’s Computer Task Group (CTG) taking center stage, with its IT systems compromised and personal info slipping through the cracks. On September 26, 2026, an unwelcome guest rooted around their network,...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Local Visibility Crisis Looms for Small Businesses

Scrolling through these fresh stats from BrightLocal's recent report, you can almost hear the alarm bells echoing across small towns and city squares. The data paints a surprisingly sobering picture: despite the fact that 71% of folks are heading straight to Google to find local businesses, only a mere 22% of small business owners are tagging it as one of their top tools...

Tune In for Post Holdings' Earnings Call this November

Crunch Time for Post Holdings: Earnings Insight Well folks, pull out your calendars because November 20 is shaping up to be a big day for those tracking Post Holdings, Inc. (NYSE:POST). If you're in the game, this upcoming conference call is your prime chance to get the scoop on how the numbers stack up for Q4 and what's brewing for fiscal year 2027. This isn't some...

Corgi Invest Shakes Up Bond ETFs with Low Fees

A Different Breed of Bond ETFs Well, folks, when you thought the ETF scene couldn't get any more crowded, Corgi Invest pops in with a pack of 14 new bond ETFs, barking up the low-expense tree like there's no tomorrow. They've dropped these puppies into the market with fees starting as low as 0.02%, aiming to take a bite out of their pricier rivals. The Alpha of Low-Cost...

Sony's Game-Changing Sensor Reshapes Medical Endoscopy

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...

QFIN Investors Eye Class Action Amid Regulatory Struggles

QFIN Shareholders Unite Amid Regulatory Storm It's not every day you see a stock nosedive by nearly 19% overnight. But when you're investing in a company like Qfin Holdings, you get ready for a wild ride, especially when regulatory changes from China come into play. That's exactly what's happening right now as investors rally around a class action lawsuit against Qfin....

California Contractors Honored for Safety Commitment

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...